Sheena Smith

Sheena Smith

Company: Vector BioPharma

Job title: Head of Program Management


Panel Discussion: War of the Payloads – Addressing the Advantages & Disadvantages of Transient VS Direct Integration 12:00 pm

• Discussing the use of non-stable integration with a DNA payload for greater safety and control • Discussing the challenges associated with stable integration, including lack of control in the context of proliferated cells • Re-thinking re-dosing strategies for enhanced efficacy • Evaluating the implications of removing lymphodepletion for in-vivo approaches, and associated effects on…Read more

day: Day 2

Precision Gene Delivery by SHREAD VLPs for Enhanced Safety and Efficacy In Vivo 1:00 pm

• Overview of Vector BioPharma’s proprietary SHielded Retargeted ADenovirus (SHREAD)-based virus-like particle (VLP) technology and key applications in cell therapy, immuno-oncology, genome editing and beyond • Interchangeable adapter technology for targeting VLP to specific tissues and cell types in vivo • Shielding and capsid engineering technologies for reducing immunogenicity and clearance of VLPsRead more

day: Day 1

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.